Tracers / [225Ac]Ac-mcp-IgG4
[225Ac]Ac-mcp-IgG4
Also written as [Ac-225]Ac-mcp-IgG4
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 0
What it is
- Compound class
- non-targeting control IgG4 antibody conjugated to mcp (MACROPA-derived chelator)
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [225Ac]Ac-mcp-IgG4, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41887735. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage 25: this agent has NO own synthesis/characterisation data in the current corpus -- the model's own extraction reasoning confirms mcp-IgG4 appears only as a non-targeting isotype-control antibody vs. the DLL3-targeting agent in the one linked article -- never characterised itself. All previously-linked runs were unlinked (see parsed-therapy.xlsx).